Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial

BACKGROUND: Nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro. However, there is no evidence of its impact on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. METHODS: In a multicentre, randomised, double-blind, placebo-controlled trial, ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocco, Patricia R.M., Silva, Pedro L., Cruz, Fernanda F., Melo-Junior, Marco Antonio C., Tierno, Paulo F.G.M.M., Moura, Marcos A., De Oliveira, Luís Frederico G., Lima, Cristiano C., Dos Santos, Ezequiel A., Junior, Walter F., Fernandes, Ana Paula S.M., Franchini, Kleber G., Magri, Erick, de Moraes, Nara F., Gonçalves, José Mário J., Carbonieri, Melanie N., Dos Santos, Ivonise S., Paes, Natália F., Maciel, Paula V.M., Rocha, Raissa P., de Carvalho, Alex F., Alves, Pedro Augusto, Proença-Módena, José Luiz, Cordeiro, Artur T., Trivella, Daniela B.B., Marques, Rafael E., Luiz, Ronir R., Pelosi, Paolo, Lapa e Silva, Jose Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758778/
https://www.ncbi.nlm.nih.gov/pubmed/33361100
http://dx.doi.org/10.1183/13993003.03725-2020

Ejemplares similares

Ejemplares similares